ITI BioChem is specialized in providing neoantigen. Neoantigens, a class of antigens that derive from tumor-specific mutations, have been long envisioned as optimal targets to distinguish tumor cells from normal cells while bypass central immune tolerance.

Now neoantigens are important targets for checkpoint blockade therapy. Cancer neoantigens are a direct consequence of somatic mutations presenting on the surface of individual cancer cells. Neoantigens are fully cancer-specific and exempt from central tolerance. Recently, technological innovations have made neoantigen discovery possible in a variety of malignancies, thus providing an impetus to develop novel immunotherapies that selectively enhance T cell reactivity for the destruction of cancer cells while leaving normal tissues unharmed.